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Combination Therapies for Treating Alzheimer's Disease
The pathobiology of Alzheimer's disease (AD) is extremely complex and not yet fully understood. AD is characterized by the clinical syndrome of a slowly progressive dementia and the classic neuropathological findings of amyloid plaques, neurofibrillary tangles, and neuronal death. 1 These histological features develop in heterogeneous patterns and in people with varying genetic predisposition, nutritional histories, and exposure to either potentially harmful or helpful environmental agents. 1 The precise chain of events leading to the characteristic pathology is not known, but it is likely to involve a cascade of events, including oxidative stress, excitotoxic damage, altered cell-cycle regulation, pathological inflammation, oxidative and excitotoxic damage, failure of trophic responses, demyelination, apoptosis, and the failure of neurotransmitter function, among others. In this context, it makes sense to consider the therapeutic potential of combining agents with different mechanisms of action in the hope that impinging on multiple aspects of the illness process may afford a greater benefit than that seen with a single agent.
What follows is a somewhat selective overview of the available clinical evidence as we see it. The reality is that relatively few studies combine what we now might consider to be the most promising strategies: most data come from earlier studies addressing putative neurotransmitter dysfunction. It is important to note that some studies were true 'combination' studies, in which multiple agents were co-administered simultaneously, and others were 'add-on' designs, in which case a second agent was administered some time after a prior therapy was initiated. This distinction is methodologically important.
Cholinergics
The earliest and most obvious efforts addressed what might happen if different cholinergic therapies were combined. There is compelling evidence for structural and functional cholinergic impairment in AD, and emerging evidence that cholinergic therapeutics might confer clinically discernible benefit.
Tacrine and Lecithin
What may have been the first combination study in AD addressed the effects of tetrahydroaminoacridine (THA) combined with lecithin. 2 Ten patients diagnosed with 'primary progressive dementia' were studied in four trials of random order: placebo, lecithin alone, THA alone, or a combination of lecithin and THA. Medications were administered in divided doses of THA 90mg and/or lecithin 180mg at three intervals over a 14-hour period. Cognitive testing was performed two hours after the final dose.
Each of the four studies was separated by a minimum of 56 hours. While highly topical for its time, the study was essentially negative.
In a double-blind, cross-over study with two sequential randomized periods of treatment lasting for eight weeks each, Gauthier et al. Co-operative Study trial, these findings have led to a marked reduction in the use of these agents, and the combination has not been advocated by any major consensus statements.
Donepezil and Alpha-tocopherol
A retrospective study 11 investigating 40 AD patients who were on combination therapy with donepezil ≥5mg daily and vitamin E ≥1,000IU
daily for at least one year were compared with historical data of patients with no AD treatment obtained from the 1986-1996 Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 12 database, which was created prior to the availability of these treatment options. The average MMSE of patients on donepezil and vitamin E declined at a significantly lower rate at the one-, two, and three-year follow-up compared with historical data from the CERAD. This study had significant inherent limitations.
Multivitamins
The combination of vitamin B 12 0.5mg and an over-the-counter nutritional supplement containing folic acid 1mg and vitamin B 6 5mg
(other vitamins and iron were also included) was tested as an adjunct to an AChEI in mild to moderate AD in 89 patients over 26 weeks. 13 The aim was to determine whether oral multivitamin supplementation containing vitamins B 6 and B 12 and folic acid would improve cognitive function and reduce serum homocysteine levels in patients with mild to moderate AD.
Although no statistical significance was found on primary or secondary outcome measures, there was a significant decline in the serum homocysteine concentration in the treatment group.
Selective Serotonin Re-uptake Inhibitors
Sertraline
Sertraline has been assessed as an adjunct to donepezil in the treatment of behavioral symptoms in outpatients with AD (MMSE between 8 and 23). Alzheimer's Disease
Fluoxetine
One preliminary study has been performed to assess the effect of a fluoxetine as an adjunct to an AChEI in AD for 12 weeks. 15 One hundred and twenty-two patients with mild to moderate AD (MMSE 10-24) were randomized to one of three arms: fluoxetine plus rivastigmine, rivastigmine alone, or placebo. There was a significant improvement in MMSE and Wechsler Memory Scale 3rd Edition (WMS-III) in both the combination group and the rivastigmine alone group, but there was no difference between these two groups. These two groups also significantly improved on the Lawton and Brody ADL scale, 16 with a statistical significance between the two groups favoring the combination group. On the Hamilton Depression Scale-17 (HAM-17), both treatment groups had significant benefit compared with placebo, but were not clinically significant compared with each other.
Memantine and Cholinergic Agents
Glutamatergic neurons are ubiquitous in the central nervous system (CNS) and are involved in learning, memory, and shaping neuronal architecture. They are the primary CNS excitatory neurons, and are predominantly 'projection' neurons, which provide information about one brain area to another. In AD, there is thought to be an overstimulation of the glutamatergic N-methyl-D-aspartate (NMDA)
receptor. This abnormal glutamate activity leads to an excessive cellular influx of calcium and sustained low-level activation of NMDA receptors.
This is thought to lead to impaired learned and neuronal death following chronic insult. 17 Memantine, an NMDA receptor antagonist, was shown to be efficacious in moderate and severe AD as monotherapy. 18, 19 Pre-clinical studies show no inhibition of AChE by memantine, and no binding to muscarinic receptors. [20] [21] [22] There is no pharmacokinetic or pharmacodynamic interaction between memantine and donepezil, 23 A post hoc analysis of this same study examined the ADCS-ADL19 in more detail. 26 Patients receiving combination therapy had statistically significantly less decline in ADLs, with item analysis showing that effects were on grooming, using the toilet, conversing, watching television, and being left alone. The addition of memantine to an AChEI was recently studied in patients with mild to moderate AD (MMSE 10-22). 27 A total of 433 patients who were on stable doses of an AChEI (donepezil, rivastigmine, or galantamine) were randomized to placebo versus memantine 20mg once daily for 24 weeks. Although memantine was well tolerated, there were no statistically significant differences in primary (ADAS-cog and CIBIC-Plus) or secondary (ADCS-ADL (23), NPI, and MMSE) outcome measures.
Conclusions
Most of the combination or add-on studies failed to show significant benefit or define best practice. Perhaps the most widely cited data come from studies in patients with mild to moderate AD, where the available evidence indicates that memantine can be used alone or in combination with a cholinesterase inhibitor, but we do not know whether one approach is truly superior to the other (and we note that donepezil alone among the cholinesterase inhibitors is also US Food and Drug Administration [FDA]-approved for the treatment of severe AD). We also do not know whether the order in which these two classes of agents are administered is important. There are many other unanswered questions, including whether the combination of memantine with other agents might show benefit and whether benefit can be seen in non-AD dementias.
The future of the study of combination therapy will inevitably be far different from its past. More novel agents, such as those attempting to normalize aberrant amyloid processing, will be combined with currently approved neurotransmitter-based therapies, and within the next five years we will begin to see trials combining novel strategies (e.g. normalizing tau phosphorylation and regulating amyloid processing)-strategies suggested by the promising pre-clinical work of Ashe, Laferla, and others. 28,29 ■ 
